Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Beneficial Effect of a Selective Adenosine A(2A) Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease

Faivre, E., Coelho, J. E., Zornbach, K., Malik, E., Baqi, Y., Schneider, M., et al. (2018). Beneficial Effect of a Selective Adenosine A(2A) Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. Frontiers in Molecular Neuroscience, 11: 235. doi:10.3389/fnmol.2018.00235.

Item is

Basisdaten

einblenden: ausblenden:
Genre: Zeitschriftenartikel

Dateien

einblenden: Dateien
ausblenden: Dateien
:
fnmol-11-00235.pdf (Verlagsversion), 3MB
Name:
fnmol-11-00235.pdf
Beschreibung:
Open Access
OA-Status:
Sichtbarkeit:
Öffentlich
MIME-Typ / Prüfsumme:
application/pdf / [MD5]
Technische Metadaten:
Copyright Datum:
-
Copyright Info:
-
Lizenz:
-

Externe Referenzen

einblenden:
ausblenden:
Beschreibung:
-
OA-Status:

Urheber

einblenden:
ausblenden:
 Urheber:
Faivre, Emilie1, Autor
Coelho, Joana E.1, Autor
Zornbach, Katja2, Autor
Malik, Enas1, Autor
Baqi, Younis1, Autor
Schneider, Marion1, Autor
Cellai, Lucrezia1, Autor
Carvalho, Kevin1, Autor
Sebda, Sheherazade1, Autor
Figeac, Martin1, Autor
Eddarkaoui, Sabiha1, Autor
Caillierez, Raphaelle1, Autor
Chern, Yijuang1, Autor
Heneka, Michael1, Autor
Sergeant, Nicolas1, Autor
Mueller, Christa E.1, Autor
Halle, Annett2, Autor
Buee, Luc1, Autor
Lopes, Luisa V.1, Autor
Blum, David1, Autor
Affiliations:
1External Organizations, ou_persistent22              
2Center of Advanced European Studies and Research (caesar), Max Planck Society, Ludwig-Erhard-Allee 2, 53175 Bonn, DE, ou_2173675              

Inhalt

einblenden:
ausblenden:
Schlagwörter: A2A; Alzheimer’s disease; adenosine receptor; amyloid; memory
 Zusammenfassung: Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) and mitigates both amyloid and Tau lesions in transgenic mouse models of the disease. While short-term treatment with A2AR antagonists have been shown to alleviate cognitive deficits in mouse models of amyloidogenesis, impact of a chronic and long-term treatment on the development of amyloid burden, associated neuroinflammation and memory deficits has never been assessed. In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A2AR antagonist MSX-3 from 3 to 9-10 months of age. At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions. Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. Together, these data support the idea that A2AR blockade is of therapeutic value for AD.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2018-07-12
 Publikationsstatus: Online veröffentlicht
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: ISI: 000438402300001
DOI: 10.3389/fnmol.2018.00235
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Frontiers in Molecular Neuroscience
  Kurztitel : Front Mol Neurosci
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Lausanne, Switzerland : Frontiers Research Foundation
Seiten: - Band / Heft: 11 Artikelnummer: 235 Start- / Endseite: - Identifikator: ISSN: 1662-5099
CoNE: https://pure.mpg.de/cone/journals/resource/1662-5099